Freedom (in English), libertà (in Italian), libertas (in Latin)...this trial will try to prove if apalutamide + intermittent ADT is non inferior to apalutamide + continuous ADT....
The LIBERTAS trial is a phase III study exploring a more personalized approach to metastatic hormone-sensitive prostate cancer (mHSPC). It investigates whether patients with undetectable PSA after 6 months of apalutamide + ADT can safely switch to intermittent rather than continuous ADT. The goal is to maintain cancer control while reducing side effects, especially hot flashes. Patients are randomized to either standard continuous therapy or a de-escalated regimen. The trial also emphasizes patient well-being, not just survival. Final efficacy results on intermittent ADT are still awaited.
